Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN   3:59:59 PM EDT
543.82
-4.38 (-0.80%)
5:06:43 PM EDT: $543.00 -0.82 (-0.15%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)58.03B
Current PE18.39
Forward PE 17.81
2yr Forward PE 13.95
See more stats
Estimates Current Quarter
Revenue$2.41 Billion
Adjusted EPS$8.32
See more estimates
10-Day MA$529.83
50-Day MA$507.52
200-Day MA$569.03
See more pivots

REGENERON PHARMACEUTICALS INC Stock, NASDAQ:REGN

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY 10591
United States of America
Phone: 9143477000
Number of Employees: 7400

Description

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its products include EYLEA injection for the treatment of neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and ARCALYST injection for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children's. It also markets Kevzara injection for the treatment of rheumatoid arthritis in adults; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. The company also develops EYLEA, trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma. Regeneron Pharmaceuticals, Inc. has collaboration agreement with Sanofi for the development of antibody-based clinical products comprising Praluent, Sarilumab, Dupixent, REGN2810, REGN3500, and REGN3767; Bayer HealthCare LLC for the development of Nesvacumab/aflibercept, which is used in ophthalmology; and with Teva and Mitsubishi Tanabe Pharma Corporation for developing Fasinumab, an antibody to nerve growth factor, as well as collaboration agreement with Intellia Therapeutics, Inc., to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. The company was founded in 1988 and is headquartered in Tarrytown, New York.